» Articles » PMID: 17519397

Noninherited Risk Factors and Congenital Cardiovascular Defects: Current Knowledge: a Scientific Statement from the American Heart Association Council on Cardiovascular Disease in the Young: Endorsed by the American Academy of Pediatrics

Overview
Journal Circulation
Date 2007 May 24
PMID 17519397
Citations 319
Authors
Affiliations
Soon will be listed here.
Abstract

Prevention of congenital cardiovascular defects has been hampered by a lack of information about modifiable risk factors for abnormalities in cardiac development. Over the past decade, there have been major breakthroughs in the understanding of inherited causes of congenital heart disease, including the identification of specific genetic abnormalities for some types of malformations. Although relatively less information has been available on noninherited modifiable factors that may have an adverse effect on the fetal heart, there is a growing body of epidemiological literature on this topic. This statement summarizes the currently available literature on potential fetal exposures that might alter risk for cardiovascular defects. Information is summarized for periconceptional multivitamin or folic acid intake, which may reduce the risk of cardiac disease in the fetus, and for additional types of potential exposures that may increase the risk, including maternal illnesses, maternal therapeutic and nontherapeutic drug exposures, environmental exposures, and paternal exposures. Information is highlighted regarding definitive risk factors such as maternal rubella; phenylketonuria; pregestational diabetes; exposure to thalidomide, vitamin A cogeners, or retinoids; and indomethacin tocolysis. Caveats regarding interpretation of possible exposure-outcome relationships from case-control studies are given because this type of study has provided most of the available information. Guidelines for prospective parents that could reduce the likelihood that their child will have a major cardiac malformation are given. Issues related to pregnancy monitoring are discussed. Knowledge gaps and future sources of new information on risk factors are described.

Citing Articles

Clinical features and genetic analysis of 471 cases of fetal congenital heart disease.

Quan Y, Luo Y, Li J, Wang T, Zhang P, Li Y BMC Pregnancy Childbirth. 2024; 24(1):780.

PMID: 39587524 PMC: 11587643. DOI: 10.1186/s12884-024-06978-y.


Fine particulate matter‑induced cardiac developmental toxicity (Review).

Meng X, Du W, Sun Z Exp Ther Med. 2024; 29(1):6.

PMID: 39534282 PMC: 11552469. DOI: 10.3892/etm.2024.12756.


Cell-based therapies reverse the heart failure-altered right ventricular proteome towards a pre-disease state.

Makkaoui N, Prasad V, Bagchi P, Carmona T, Li K, Latham O Stem Cell Res Ther. 2024; 15(1):420.

PMID: 39533351 PMC: 11559167. DOI: 10.1186/s13287-024-04009-3.


Identifying at-risk patients for congenital heart disease using integrated predictive models and fuzzy clustering analysis: A cross-sectional study.

Salehi A, Khedmati M Heliyon. 2024; 10(20):e39609.

PMID: 39498045 PMC: 11532873. DOI: 10.1016/j.heliyon.2024.e39609.


Validation of a Paralimbic-Related Subcortical Brain Dysmaturation MRI Score in Infants with Congenital Heart Disease.

Reynolds W, Votava-Smith J, Gabriel G, Lee V, Rajagopalan V, Wu Y J Clin Med. 2024; 13(19).

PMID: 39407833 PMC: 11476423. DOI: 10.3390/jcm13195772.